A supplemental biologics license application has been submitted to the FDA for nogapendekin alfa plus Bacillus Calmette-Guérin in papillary non-muscle invasive bladder cancer.

Perspective from Philip Abbosh, MD, PhD A urinary DNA methylation test showed potential for detecting high-grade or invasive bladder cancer, according to results of a prospective multicenter study.

Matt Galsky, MD, delved into the recent approval of a perioperative durvalumab regimen in muscle-invasive bladder cancer.

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

25% of bladder cancer patients are diagnosed with Muscle-Invasive Bladder Cancer (MIBC). As the name implies, the cancer has penetrated deep into the bladder wall and invaded the muscle layer.

The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01.

Lead investigational program, NDV-01, for High-Grade Non-Muscle Invasive Bladder Cancer, is being evaluated in a Phase 2 study. In addition, preparations are underway to advance sepranolone, a Phase ...

The oral drug – Johnson & Johnson's Balversa (erdafitinib) – will become an option for adults with metastatic or unresectable ...

Research published in ACS Central Science reveals a method that uses pulsed infrared light to identify molecular profiles in ...

Evolveimmune Therapeutics Inc. has announced a translational research collaboration with Memorial Sloan Kettering Cancer Center (MSK) to investigate the expression of a new tumor target – UL binding ...

A new, AI-powered test can detect the molecular "fingerprints" of cancer in a patient's blood using flashes of infrared light ...